Supernus Pharmaceuticals, Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026The company is combining with another pharmaceutical company, which will significantly change the business and ownership structure.
Management will explain merger plans to investors, helping you understand how the deal works and what happens next.
Quarterly earnings show whether the company made or lost money, telling you if the business is healthy.
This signed deal means the merger is officially happening; Supernus shareholders will get 1.5401 Indivior shares per share owned.
The company is scheduling release of earnings numbers so investors know when to expect financial performance details.
Shareholders voted on company leadership; Frederick Hudson and Charles Newhall were elected to guide the company until 2029.
Stocky reads Supernus Pharmaceuticals, Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Supernus Pharmaceuticals, Inc.'s most recent tracked filing was a 8-K on 3 Aug 2026: Announces merger of equals with Indivior Pharmaceuticals.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.